Abingworth, a venture fund established in 1973, operates from London, United Kingdom. The fund, led by partner Tim Haines, specializes in Seed to Series D investments within the BioTech, Healthcare, and Medical Device sectors. Abingworth has backed notable companies like Wugen, Q32 Bio, and Tizona Therapeutics. With a total of 166 investments and 78 exits, Abingworth prides itself on fostering collaborations with life sciences entrepreneurs to drive innovation in the industry. For more information, visit their website at www.abingworth.com.